Novo Nordisk (ADR) (NVO)
Develops GLP-1 and insulin medicines for diabetes, obesity and rare diseases.
$39.33
vs last close−0.48 (−1.19%)
In millions of USD, except per-share figures · converted from DKK at the latest rate
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,990 | 10,082 | 10,003 | 10,418 | 10,915 | 13,115 | 11,953 | 11,764 | 11,476 | 12,114 | 14,821 | 12,014 |
| Cost of revenue | 1,487 | 1,533 | 1,518 | 1,573 | 1,731 | 1,994 | 1,973 | 1,966 | 2,741 | 2,319 | 2,081 | 2,617 |
| Gross profit | 7,503 | 8,549 | 8,485 | 8,845 | 9,185 | 11,122 | 9,980 | 9,798 | 8,736 | 9,796 | 12,739 | 9,397 |
| 3,384 | 4,452 | 3,610 | 4,876 | 4,007 | 5,499 | 4,042 | 4,678 | 5,111 | 4,938 | 3,613 | 5,254 | |
| Research & development | 1,244 | 1,601 | 1,317 | 2,475 | 1,452 | 2,113 | 1,578 | 1,789 | 2,356 | 2,242 | 1,574 | 2,723 |
| 2,154 | 2,851 | 2,206 | 2,463 | 2,540 | 3,104 | 2,466 | 2,885 | 2,737 | 2,669 | 2,023 | 2,496 | |
| Selling & marketing | 1,962 | 2,628 | 2,029 | 2,286 | 2,328 | 2,863 | 2,279 | 2,684 | 2,448 | 2,432 | 1,849 | 2,296 |
| General & administrative | 192 | 223 | 177 | 177 | 212 | 242 | 187 | 201 | 288 | 237 | 174 | 200 |
| Other expenses | −15 | 0 | 87 | −62 | 15 | 281 | −2 | 4 | 18 | 27 | 16 | 36 |
| Operating income | 4,120 | 4,097 | 4,875 | 3,970 | 5,177 | 5,623 | 5,938 | 5,120 | 3,625 | 4,858 | 9,126 | 4,142 |
| 176 | 131 | 11 | −92 | 86 | −181 | −269 | 54 | 281 | 375 | 391 | −28 | |
| Interest income | 508 | 0 | 328 | 147 | 212 | 599 | 524 | 813 | 281 | 375 | 927 | 201 |
| Interest expense | 332 | 140 | 317 | 239 | 126 | 780 | 793 | 759 | 0 | 0 | 536 | 230 |
| Other non-operating income | −508 | 191 | −328 | −147 | −212 | −599 | −524 | −813 | −281 | −375 | −927 | −201 |
| Income before tax | 4,296 | 4,228 | 4,886 | 3,878 | 5,263 | 5,443 | 5,669 | 5,174 | 3,906 | 5,233 | 9,517 | 4,114 |
| Income tax expense | 855 | 866 | 997 | 809 | 1,084 | 1,122 | 1,224 | 1,118 | 844 | 1,116 | 2,084 | 901 |
| Net income from continuing operations | 3,441 | 3,362 | 3,889 | 3,069 | 4,179 | 4,321 | 4,444 | 4,057 | 3,062 | 4,116 | 7,433 | 3,213 |
| Net income | 3,441 | 3,362 | 3,889 | 3,069 | 4,179 | 4,321 | 4,444 | 4,057 | 3,062 | 4,116 | 7,433 | 3,213 |
| EPS, basic | $0.77 | $0.75 | $0.87 | $0.69 | $0.94 | $0.97 | $1.00 | $0.91 | $0.69 | $0.93 | $1.67 | $0.73 |
| EPS, diluted | $0.77 | $0.75 | $0.87 | $0.69 | $0.94 | $0.97 | $1.00 | $0.91 | $0.69 | $0.92 | $1.67 | $0.73 |
| Weighted average shares, basic | 4,477 | 4,465 | 4,460 | 4,458 | 4,454 | 4,454 | 4,440 | 4,447 | 4,446 | 4,448 | 4,443 | 4,428 |
| Weighted average shares, diluted | 4,489 | 4,477 | 4,471 | 4,465 | 4,461 | 4,461 | 4,446 | 4,447 | 4,447 | 4,448 | 4,449 | 4,436 |
| EBITDA | 5,014 | 4,364 | 5,649 | 5,471 | 5,718 | 7,018 | 7,048 | 6,673 | 5,093 | 6,084 | 10,593 | 5,921 |
| Depreciation & amortization | 386 | 458 | 446 | 1,354 | 329 | 796 | 586 | 740 | 1,187 | 851 | 541 | 1,577 |
| EBIT | 4,627 | 3,906 | 5,203 | 4,117 | 5,389 | 6,222 | 6,462 | 5,933 | 3,906 | 5,233 | 10,052 | 4,343 |